Introduction: Cannabidiol (CBD) as Epidiolex®(GW Pharmaceuticals) was recently
approved by the US Food and Drug Administration (FDA) to treat rare forms of epilepsy in …

Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a
compound that does not produce the typical subjective effects of marijuana. Objectives: The …

Research in the cannabinoid field, namely on phytocannabinoids, the endogenous
cannabinoids anandamide and 2-arachidonoyl glycerol and their metabolizing and synthetic …

The development of multidrug‐resistant bacteria has revealed the need for new
antimicrobial compounds. Cannabis sativa preparations have a long history of medical …

Multiple cannabinoids derived from the marijuana plant have potential therapeutic benefits
but most have not been well investigated, despite the widespread legalization of medical …

Neuropsychiatric disorders such as schizophrenia are associated with cognitive impairment,
including learning, memory and attention deficits. Antipsychotic drugs are limited in their …

Background and objectives Cognitive impairment is a core symptom domain of
schizophrenia, neurological disorders and substance abuse. It is characterised by deficits in …

Most diabetic patients describe moderate to severe pain symptoms whose pharmacological
treatment is palliative and poorly effective. Cannabidiol (CBD) has shown promising results …

The literature provides scientific evidence for the beneficial effects of cannabidiol (CBD), and
these effects extend beyond epilepsy treatment (eg, Lennox–Gastaut and Dravet …

Oxidative stress and inflammation is likely to be a major step in the development of sepsis-
associated encephalopathy (SAE) and long-term cognitive impairment. To date, it is not …